A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

Inclusion Criteria:

1. Participant must be 18 to 70 years of age inclusive (except for dose escalation mustbe 18 to 65 years of age) at the time of signing the informed consent.

2. Has spastic hemiparesis following stroke or Traumatic brain injury (TBI)

3. Is at least 6 months post-stroke or TBI

4. Has never received BoNT or if previously treated, should have received their lastinjection of any commercialized BoNT-A or B at least 4 months prior to studyBaseline

5. Has a MAS score ≥2 in the (PTMG) to be injected

6. Is eligible to receive a total recommended dose 1000 U Dysport in the upper limbwhen applicable.

7. Has angle of spasticity ≥5° in the PTMG to be injected.

8. Does not have any fixed contractures as defined by:

• Complete fingers extension with Angle of arrest at slow speed (Tardieu Scale) (XV1) ≥160°

• Complete wrist extension with XV1 ≥90°

• Complete elbow extension with XV1 ≥160°

9. Physiotherapy, occupational therapy, splinting, use of benzodiazepine, and musclerelaxants had to be stable from at least 30 days preceding the study Baseline up tothe Month 3 visit, and whenever possible until the end of the study.

10. In good health (i.e. absence of any uncontrolled systemic disease or othersignificant medical condition) as determined by medical history, physical andneurological examinations, clinical laboratory studies, electrocardiograms (ECGs),vital signs, and Investigator's judgment prior to randomization

11. Male and female participants Contraceptive use by men or women should be consistentwith local regulations regarding the methods of contraception for thoseparticipating in clinical studies.

Male participants must agree that, if their partner is at risk of becoming pregnant, they will use an effective method of contraception. The participants must agree to use the contraception during the whole period of the study.

A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: Is a woman of non-childbearing potential (WONCBP) or is a woman of childbearing potential (WOCBP) and using an acceptable contraceptive method (until the end of the study). The investigator should evaluate the potential for contraceptive method failure in relationship to the first dose of study intervention. A WOCBP must have a negative highly sensitive pregnancy test.

Exclusion Criteria:

1. Any medical condition (including severe dysphagia or airway disease) that mayincrease, in the opinion of the investigator, the likelihood of adverse events (AEs)related to BoNT treatment.

2. Known disease of the neuromuscular junction (e.g. Lambert-Eaton myasthenic syndrome,myasthenia gravis or amyotrophic lateral sclerosis etc.).

3. Has a history of hypersensitivity to the investigational medicinal products (orother BoNTs) or any excipient used in their formulation.

4. Clinically diagnosed significant anxiety disorder, or any other significantpsychiatric disorder (e.g. depression) that might interfere with the participant'sparticipation in the study.

5. Likely treatment with any serotype of BoNT for any condition during the study.

6. Undergone previous surgery to treat spasticity in the affected upper limb.

7. Has initiated physiotherapy within 30 days prior to Baseline (if physiotherapyinitiated more than 30 days prior to Baseline and ongoing, the therapy regimenshould be maintained at the same frequency and intensity throughout the study ifpossible or at least up to 3-months post-injection).

8. Has received previous treatment with phenol and or alcohol in the targeted upperlimb any time before the study.

9. Has been treated or is likely to be treated with intrathecal baclofen during the 30days prior to study Baseline or during the course of the study.

10. Current or planned treatment with any medications that interfere either directly orindirectly with neuromuscular transmission, such as curare-like non depolarisingagents, lincosamides, polymyxins, anticholinesterases and aminoglycosideantibiotics, within 30 days prior to Baseline.

11. Use of concomitant therapy which, in the investigator's opinion, would interferewith the evaluation of the safety or efficacy of the study intervention, includingmedications affecting bleeding disorders. For patients taking vitamin K antagonists,the INR values should be controlled (between 2 and 3)

12. Currently planned or a history of tendon lengthening surgery, significantcontracture or muscle atrophy at target joint or muscle in the past 6 months priorto Screening.

13. Use of any experimental device within 30 days or use of any treatment with anexperimental drug within five times the documented terminal half-life of therespective drug or its metabolites or if the half-life is unknown within 30 daysprior to the start of the study (prior to Baseline) and during the conduct of thestudy.

14. Presence of any other condition (e.g. neuromuscular disorder, muscular dystrophies,cancer cachexia, sarcopenia or other disorder that could interfere withneuromuscular function), laboratory finding or circumstance that, in the judgment ofthe investigator, might increase the risk to the participant or decrease the chanceof obtaining satisfactory data to achieve the objectives of the study.

15. Pregnant or lactating women, or women of childbearing potential not willing topractice a highly effective form of contraception method at the beginning of thestudy, for the duration of the study and for the duration of the study

16. Inability to understand protocol procedures and requirements

17. Infection at the injection site(s)

18. A history of drug or alcohol abuse

19. Male participants who are not vasectomised and who have female partners ofchildbearing potential and are not willing to use condoms with spermicide throughoutstudy participation.